Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.
Jakesz R, Hausmaninger H, Haider K, Kubista E, Samonigg H, Gnant M, Manfreda D, Tschurtschenthaler G, Kolb R, Stierer M, Fridrik M, Mlineritsch B, Steindorfer P, Mittlböck M, Steger G. Jakesz R, et al. Among authors: mittlbock m. J Clin Oncol. 1999 Jun;17(6):1701-9. doi: 10.1200/JCO.1999.17.6.1701. J Clin Oncol. 1999. PMID: 10561206 Clinical Trial.
A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer.
Schippinger W, Jagoditsch M, Sorré C, Gnant M, Steger G, Hausmaninger H, Mlineritsch B, Schaberl-Moser R, Mischinger HJ, Hofbauer F, Holzberger P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group. Schippinger W, et al. Among authors: mittlbock m. Br J Cancer. 2005 May 9;92(9):1655-62. doi: 10.1038/sj.bjc.6602555. Br J Cancer. 2005. PMID: 15856042 Free PMC article. Clinical Trial.
Assessing the TP53 marker type in patients treated with or without neoadjuvant chemotherapy for resectable colorectal liver metastases: a p53 Research Group study.
Pilat N, Grünberger T, Längle F, Mittlböck M, Perisanidis B, Kappel S, Wolf B, Starlinger P, Kührer I, Mühlbacher F, Kandioler D. Pilat N, et al. Among authors: mittlbock m. Eur J Surg Oncol. 2015 May;41(5):683-9. doi: 10.1016/j.ejso.2015.02.003. Epub 2015 Feb 25. Eur J Surg Oncol. 2015. PMID: 25773284
• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.
Kappel-Latif S, Zacherl J, Hejna M, Westerhoff M, Tamandl D, Ba-Ssalamah A, Mittlböck M, Wolf B, Wrba F, Kührer I, Pluschnig U, Schoppmann SF, Függer R, Zwrtek R, Glaser K, Karner J, Längle F, Wenzl E, Roka R, Öfner D, Tschmelitsch J, Hold M, Keil F, Gnant M, Kandioler D; Pancho trialists and for the Medical University of Vienna p53research group. Kappel-Latif S, et al. Among authors: mittlbock m. Eur Surg. 2018;50(4):160-166. doi: 10.1007/s10353-018-0527-z. Epub 2018 Jun 11. Eur Surg. 2018. PMID: 30559831 Free PMC article.
Tumor recurrence after oLTX.
Gruenberger T, Windhager T, Gnant M, Mittlböck M, Steininger R, Herbst F, Muehlbacher F. Gruenberger T, et al. Among authors: mittlbock m. Transpl Int. 1996;9 Suppl 1:S151-4. doi: 10.1007/978-3-662-00818-8_37. Transpl Int. 1996. PMID: 8959813
149 results